Download presentation
Presentation is loading. Please wait.
Published byDorothy Cunningham Modified over 9 years ago
1
Hale & Tempest Global Generics Marketplace Dr. Brian W Tempest www.briantempest.com brian.tempest@clara.co.uk UK 18,19,20 March 2014
2
Hale & Tempest
3
1. Global Healthcare 2. Big Pharma 3.Global Generic Marketplace 4.Global Generic Companies 5.Indian Generic Marketplace 6.Indian Generic Companies 7. Country Generic Markets 8. Biosimilars 9. Generic Distribution 10. Over The Counter Consumer Medines 11. Contract Manufacturers
4
Hale & Tempest Global Healthcare & Big Pharma Chesapeake Dr. Brian W Tempest www.briantempest.com brian.tempest@clara.co.uk UK March 2014
5
Hale & Tempest 1. Global Healthcare
6
Hale & Tempest There are only a few certain things Source: T Stevenson, Fidelity Worldwide Investment Director, S Telegraph April 21 2013 Populations growth Ageing Expansion of the World’s Middle Classes Increasing demand for healthcare is as close to given as investors can hope for
7
Hale & Tempest Rise of the Middle Classes source: Frost & Sullivan
8
Hale & Tempest Aging in OECD source: EGA
9
Hale & Tempest Global Healthcare Growth by Region Source: Sunday Telegraph April 21 2013
10
Hale & Tempest Healthcare costs versus GDP & Wages
11
Hale & Tempest Public Health as % of GDP Source: UNDP 15 October 2012 Cuba 9.7% USA 9.5% France 9.3% UK 8.1% Brazil 4.2% RSA 3.9% Russia 3.2% China 2.7% India 1.2%
12
Hale & Tempest Military vs Health source: FT 24February 2014
13
Hale & Tempest Public Health Reform Everywhere
14
Hale & Tempest OECD Healthcare Expenditure Growth source: Annalisa Belloni OECD at EGA Conference 13 June 2013
15
Hale & Tempest Everybody Concerned about Health Costs
16
Hale & Tempest Healthcare as % of Government Spend source: WHO, Jefferies
17
Hale & Tempest Public & Private Healthcare as % of GDP source: WHO, India is <4%
18
Hale & Tempest How Easy to Start a Business in EMs source: Mint 13 October 2013
19
Hale & Tempest Number of Companies with Active R&D Pipelines source: Citeline Pharma R&D Annual Review 2013
20
Hale & Tempest Worldwide R&D Spend source: Evaluate Pharma 23 June 2013
21
Hale & Tempest R&D Spending by Country source: Economist March 22 2014
22
Hale & Tempest Rise of Asia R&D source: Economist March 22 2014
23
Hale & Tempest Emerging Markets Pharma Markets, $b Source: Citi Research August 2013
24
Hale & Tempest Value of EM Bourses - limited availability source: January 18 2014 Economist
25
Hale & Tempest OECD vs. BRICS source: FT 9 October 2013
26
Hale & Tempest Emerging Markets source: Business India December 8 2013
27
Hale & Tempest The Need for Universal Healthcare source: ET 2 Aug 2013
28
Hale & Tempest Healthcare will explode further in Asia
29
Hale & Tempest Asian Healthcare Expenditure $b source: EIU for countries PRC, HK, I, Ind, M, P, Si, SK, Tw, Th, V
30
Hale & Tempest Pharmaceutical Imports into USA source: Chemistry World July 2012
31
Hale & Tempest Cipla - Washington Post Ad
32
Hale & Tempest Sovaldi (sofosbuvir) for Hepatitis C Source: Pharmatimes February 7 2014 In USA Gilead Sciences charges Sovaldi at $1000 a day for a 12 week course -$84,000 The cost of manufacture of the same 12 week course is $68 to $136 according to MSF generating a gross profit over 99% In India and other emerging markets Gilead plans to charge $2,000 for a 24 week course leading to a gross profit of 86%
33
Hale & Tempest Evolving Emerging Markets IP Policy Source: Leaky Pharma 27 Jan 2014 “This is genocide, This can sentence South Africans to death” – RSA Health Minister (Motsoaldi) 1998 Big Pharma, Merck vs Mandela, PR disaster Enhanced Therapeutic Efficacy vs Incremental Efficacy 2014 Merck, PhRMA, Lobbyist PAE vs RSA IP policy OECD growth +1-4% vs Emerging Markets at +10-13% WHO Executive Board – “we cannot be sidetracked from our course of action of defending public health and the right to life” (DG Precious Matsoso)
34
Hale & Tempest Davos 2014 -Ten Global Risks of Highest Concern source: Davos 2014
35
Hale & Tempest Aid by Country source: Economist 12 April 2014
36
Hale & Tempest 2. Big Pharma
37
Hale & Tempest Big Pharma Business Model Broken source: Pharmatimes World News April 2012
38
Hale & Tempest Pharma in Crisis Source: Pharmatimes February 2013
39
Hale & Tempest A Slide from a UK Headhunter
40
Hale & Tempest Top 10 Marketing Settlements Source: Fiercepharma 26 June 2012 GSK $3b 2012 Pfizer $2.3b 2009 J&J $2.2b 2012 Abbott 1.6b 2012 Lilly $1.4b 2009 Merck $1.0b 2011 Serono $0.7b 2005 Perdue $0.7b 2007 Allergan $0.6b 2010
41
Hale & Tempest A Pfizer Decade of Bribery source: FT August 7 2012
42
Hale & Tempest The Biggest Healthcare Fraud in History Source: Daily Mail 3 July 2012
43
Hale & Tempest China Bribery Investigations source: Jefferies November 2013
44
Hale & Tempest Emerging Markets are Not so Easy
45
Hale & Tempest Will Big Pharma Change?
46
Hale & Tempest Or be like Popeye the sailor man “I Yam what I Yam what I Yam”
47
Hale & Tempest The Strategic Changes by Big Pharma Source: FT December 5 2012, Franz Humer, Roche Chairman Possible to cut 30-50% off development costs via CT efficiencies Shift from product focus to patient focus using diagnostic tools In Europe there isn’t one Government or politician interested in the health of the Industry USA & Latin American countries open to rewarding innovation Industry has to change fundamentally how it manages costs Leaner headquarters & smaller central functions Division of the industry into 2 parts A Innovative businesses able to charge a premium price B Large scale manufacturers who can compete on cost
48
Hale & Tempest Divestment & Spin Off Strategies Source: IPA 2013 Novartis - Blood Diagnostics, Animal Health, OTC, Vaccines Bayer - Bayer Material Sciences likely Abbott - Abbvie (pharma assets) Pfizer - Nutrition, Zoetis Animal Health Merck - separate growth businesses from value businesses, Consumer OTC GSK - tail products to Aspen, drinks brands J&J - Diagnostics
49
Hale & Tempest 2013 The Year of 8 Blockbusters source: Evaluate March 2014
50
Hale & Tempest 2013 the 8 Blockbusters source: Evaluate March 2014
51
Hale & Tempest Big Pharma Top 10 by 2012 Sales Source: FiercePharma 29 November 2013
52
Hale & Tempest Top 10 Medtech Companies source: Evaluate Pharma, 23 September 2013
53
Hale & Tempest Pharma & Medtech Global Markets source: Evaluate 23 September 2013
54
Hale & Tempest Global Pharma Sales source: Evaluate April 2014
55
Hale & Tempest Sales at Risk source: Evaluate April 2014
56
Hale & Tempest Global Pharma sales lost & sales gained source: Evaluate March 2014
57
Hale & Tempest Biggest Expected Launches of 2014 source: EvaluatePharma
58
Hale & Tempest Strength of Local Companies source: IMS May 2012
59
Hale & Tempest Big Pharma Top Risers & Fallers in 2013 source: Evaluate March 2014
60
Hale & Tempest 2013 a healthy year for Pharma source: Evaluate March 2014
61
Hale & Tempest Thank You brian.tempest@clara.co.uk www.briantempest.com
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.